Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled...

Area of Science:

• Cardiology
• Cardiovascular Research
• Pharmacology

Background:

• Remote ischemic preconditioning (RIPC) protects against myocardial ischemia-reperfusion injury during percutaneous coronary revascularization.
• Ranolazine is an anti-ischemic drug used for chronic angina but its combined effect with RIPC in PCI patients is understudied.

Purpose of the Study:

• To investigate the combined effects of ranolazine pretreatment and RIPC in patients undergoing percutaneous coronary interventions (PCIs).

Main Methods:

• A prospective study enrolled 150 patients undergoing nonemergent percutaneous coronary revascularization.
• Patients were divided into three groups: control, RIPC only, and RIPC with ranolazine pretreatment.
• Serum enzyme levels (troponin I, CPK, CK-MB) were monitored post-procedure.

Main Results:

• The ranolazine group exhibited significantly lower increases in troponin I levels compared to the control group up to 24 hours.
• Significantly lower CPK levels were observed in the ranolazine group compared to the preconditioning group at 4, 10, and 24 hours.
• The ranolazine group also showed significantly lower CK-MB levels at 10 hours compared to the control group.

Conclusions:

• Combining RIPC with ranolazine pretreatment may reduce ischemia induction during scheduled coronary procedures.
• Lower myocardial enzyme levels in the combined treatment group suggest a protective effect against ischemia-reperfusion injury.